Vaxart Q1 2026 Earnings Report

Vaxart EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.02
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Vaxart Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $65.50 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vaxart Announcement Details

• Quarter: Q1 2026
• Date: 5/11/2026
• Time: After Market Closes
• Conference Call Date: Friday, May 8, 2026
• Conference Call Time: 4:30PM ET

Vaxart (OTCMKTS:VXRT) is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development. Among these are an oral tablet for norovirus, an oral influenza vaccine, and VXA-CoV2-1, an oral COVID-19 vaccine candidate. Vaxart has reported data from Phase I and Phase II clinical trials demonstrating favorable safety profiles and immune responses that support further clinical evaluation. In addition to its lead programs, Vaxart is exploring applications of its platform for prophylactic and therapeutic vaccines against other respiratory and enteric pathogens.

Headquartered in South San Francisco, California, Vaxart collaborates with academic institutions and government agencies to advance its oral vaccine technology. The company’s management team brings together experienced professionals in vaccine R&D, regulatory affairs, and commercial strategy, guiding Vaxart through clinical and regulatory milestones. By focusing on ease of administration and global distribution, Vaxart seeks to address unmet needs in vaccine access and public health preparedness.